The international study, involving 24 medical centers in the United States and Europe, will be presented at the American Society of Clinical Oncology (http://www.asco.org/) annual meeting June 4-8, 2010, in Chicago.
Forty-five percent of patients with transformed lymphoma treated with lenalidomide responded positively to this immunomodulatory medication, which kills lymphoma cells by activating the body's natural killer cells and by interrupting cancer cell signaling that leads to cell death. Of those patients, 21 percent showed complete remission, some for more than a year.
Transformed lymphoma is an aggressive form of blood cancer. With current therapies, patients have a median survival rate of 1.7 years. In comparison, patients with indolent or slow-growing lymphoma can live 10 to 20 years with the disease. However, over the course of a decade, about 30 percent of those with indolent lymphoma develop transformed lymphoma.
"The study results show a remarkable response rate for transformed lymphoma patients who have a very poor prognosis," says Craig Reeder, M.D. (http://www.mayoclinic.org/bio/10010343.html), Mayo Clinic hematologist (http://www.mayoclinic.org/hematology-oncology-sct/) and principal investigator for the phase II study at Mayo Clinic's Arizona (http://www.mayoclinic.org/arizona/) campus. Phase II studies typically include no more than 300 patients and are designed to evaluate the effectiveness of a specific therapy.
The study included 217 patients with aggressive lymphoma. Of those, 33 had transformed lymphoma and were treated with lenalidomide. These patients ranged in age from 42 to 84. More than half had stage IV disease, where the lymphoma has spread to multiple sites or organs. All patients had been treated with chemotherapy and some with stem cell transplant to curtail the cancer. The median number of previous treatments was four and ranged up to 12.
Patients took lenalidomide pills (25 mg) daily for 21 days. For seven days, no medication was given. The medication continued until signs of cancer progression. Overall, 45 percent of patients responded positively to the therapy, but results varied by the particular type of transformed lymphoma.
For transformed follicular lymphoma, the most common form of the illness, 13 of the 23 patients (57 percent) in this subgroup responded positively to lenalidomide. Ten patients with other types of transformed lymphoma did not respond. They included transformed chronic lymphocytic leukemia, small lymphocytic lymphoma and others.
Dr. Reeder notes that while the number of patients treated with lenalidomide was small, the results are promising because of the response rate, the length of the response, and the simplicity of treatment. In patients who responded, the positive effect of lenalidomide was seen for a median of nearly 13 months. Compared to chemotherapy drugs, lenalidomide is easy to administer and is well tolerated. "Its appeal is that it's not toxic to the patient," he says. Side effects were considered mild and included low white blood cell counts.
Lenalidomide is approved by the U.S. Food and Drug Administration to treat multiple myeloma and certain types of myelodysplastic syndrome. Mayo Clinic researchers and others have been studying its potential as a lymphoma treatment for about two years. Further studies are needed to confirm its role in treating patients with transformed lymphoma.
VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Craig Reeder, are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2010/05/26/study-identifies-promising-treatment-for-aggressive-lymphoma/).
About Mayo Clinic
For more than 100 years, millions of people from all walks of life have found answers at Mayo Clinic. These patients tell us they leave Mayo Clinic with peace of mind knowing they received care from the world's leading experts. Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. At Mayo Clinic, a team of specialists is assembled to take the time to listen, understand and care for patients' health issues and concerns. These teams draw from more than 3,700 physicians and scientists and 50,100 allied staff that work at Mayo Clinic's campuses in Minnesota, Florida, and Arizona; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. To best serve patients, Mayo Clinic works with many insurance companies, does not require a physician referral in most cases and is an in-network provider for millions of people. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your general health information.
Karl Oestreich | EurekAlert!
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine